Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
BioAge, IPO
Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO
Obesity drug developer
BioAge Labs
(BIOA) has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at the midpoint. Sofinnova Venture Partners, a leading
BioAge
...
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a private placement.
Drugmaker seeks $157.5M in IPO, placement
BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg reported Sept. 18.
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015 and plans to list on the Nasdaq under the symbol BIOA.
BioAge Labs Readies $100 Million IPO Plan For Obesity Treatment
BioAge Labs, Inc. is seeking $100 million in an IPO to fund its clinical trials for obesity and insulin sensitivity treatments. The company’s lead drug, Azelaprag, is in Phase 2 trials.
Obesity drug developer BioAge seeks up to $587 million valuation in US IPO
(Corrects bullet 2 and paragraph 5 to say drug is being tested along with GLP-1 treatments, not classified as a GLP-1 drug)(Reuters) -Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States,
Obesity drugmaker BioAge targets $158 million in IPO
The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday
pharmaphorum
13d
BioAge's $100m IPO, and other biotech financings
Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), ...
BioSpace
15d
Lilly Partner BioAge Files for IPO to Advance Obesity Candidate
BioAge will use the proceeds from the initial public offering to move its oral apelin receptor agonist azelaprag past its ...
2d
Health News | Today's Latest Stories | Reuters
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Kentucky judge fatally shot
Makes MLB history
Cancels appearance w/ Duda
Boy kills bear, saves father
30 yrs in prison for assault
To get a second moon
Ban called for in TX schools
Collapse hazard recall
Vows to remain in race
Brazil threatens daily fines
Deal to build new arena
Families lose appeal
COVID, Wuhan market link
FTC on privacy controls
Rally attendees injured
EU warns Apple
Overdose deaths drop in US
NYC subway joyride arrest
Dow, S&P hit record highs
160M euros to Ukraine
Existing home sales drop
Gun case sentencing delay
Retires after 17 seasons
Los Angeles dengue cases
Joins Motion Picture Assn.
Hails economic progress
US healthcare system falls
UN backs Palestine
Man charged for threats
To receive Holbrooke award
AC mayor, wife indicted
Retaliated against scientists
US jobless claims fall
Feedback